Allelic variation in normal human FBN1 expression in a family with Marfan syndrome:: a potential modifier of phenotype?

被引:97
作者
Hutchinson, S
Furger, A
Halliday, D
Judge, DP
Jefferson, A
Dietz, HC
Firth, H
Handford, PA [1 ]
机构
[1] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[3] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England
[4] Addenbrookes Hosp, Dept Med Genet, Cambridge CB2 2QQ, England
关键词
D O I
10.1093/hmg/ddg241
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
FBN1 mutations cause Marfan syndrome (MFS), an autosomal dominant disorder of connective tissue. One of the unexplained features of MFS is the pathogenic mechanism that leads to marked inter- and intra-familial clinical variability, despite complete disease penetrance. An FBN1 deletion patient [46,XXdel(15)(q15q22.1)] was identified whose fibrillin-1 protein and mRNA levels were significantly higher than expected for a single FBN1 allele. This suggested that allelic variation in normal FBN1 expression might occur in MFS families, and have potential clinical implications particularly for those with premature termination codon (PTC) mutations who usually display low levels of expression from the mutant allele due to nonsense-mediated decay (NMD). RNA analyses identified a variable reduction in total FBN1 transcript (78 +/- 2.2 to 27.3 +/- 2.3%) in three related individuals carrying PTC-causing mutation 932insT, compared with unaffected control individuals. Both pulse chase analysis of fibrillin-1 biosynthesis and RNase protection analyses demonstrated that these differences were due to variation in the expression of the normal FBN1 allele and not NMD of mutant RNA. We suggest that differences in normal FBN1 expression could contribute to the clinical variability seen in this family with MFS, and should be considered as a potential modifier of phenotype in other cases of MFS.
引用
收藏
页码:2269 / 2276
页数:8
相关论文
共 34 条
[1]   Dural ectasia in the Marfan syndrome: MR and CT findings and criteria [J].
Ahn, NU ;
Sponseller, PD ;
Ahn, UM ;
Nallamshetty, L ;
Rose, PS ;
Buchowski, JM ;
Garrett, ES ;
Kuszyk, BS ;
Fishman, EK ;
Zinreich, SJ .
GENETICS IN MEDICINE, 2000, 2 (03) :173-179
[2]   Transcriptional regulation of the human type I collagen α2 (COL1A2) gene by the combination of two dinucleotide repeats [J].
Akai, J ;
Kimura, A ;
Hata, RI .
GENE, 1999, 239 (01) :65-73
[3]   QUANTITATIVE DIFFERENCES IN BIOSYNTHESIS AND EXTRACELLULAR DEPOSITION OF FIBRILLIN IN CULTURED FIBROBLASTS DISTINGUISH 5 GROUPS OF MARFAN-SYNDROME PATIENTS AND SUGGEST DISTINCT PATHOGENETIC MECHANISMS [J].
AOYAMA, T ;
FRANCKE, U ;
DIETZ, HC ;
FURTHMAYR, H .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (01) :130-137
[4]   POLY(A) SITE SELECTION IN THE HIV-1 PROVIRUS - INHIBITION OF PROMOTER-PROXIMAL POLYADENYLATION BY THE DOWNSTREAM MAJOR SPLICE DONOR SITE [J].
ASHE, MP ;
GRIFFIN, P ;
JAMES, W ;
PROUDFOOT, NJ .
GENES & DEVELOPMENT, 1995, 9 (23) :3008-3025
[5]  
Béroud C, 2000, HUM MUTAT, V15, P86, DOI 10.1002/(SICI)1098-1004(200001)15:1<86::AID-HUMU16>3.0.CO
[6]  
2-4
[7]   GENOMIC SEQUENCING [J].
CHURCH, GM ;
GILBERT, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (07) :1991-1995
[8]  
DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO
[9]  
2-R
[10]   4 NOVEL FBN1 MUTATIONS - SIGNIFICANCE FOR MUTANT TRANSCRIPT LEVEL AND EGF-LIKE DOMAIN CALCIUM-BINDING IN THE PATHOGENESIS OF MARFAN-SYNDROME [J].
DIETZ, HC ;
MCINTOSH, I ;
SAKAI, LY ;
CORSON, GM ;
CHALBERG, SC ;
PYERITZ, RE ;
FRANCOMANO, CA .
GENOMICS, 1993, 17 (02) :468-475